<DOC>
	<DOCNO>NCT00131612</DOCNO>
	<brief_summary>For many year scientist cancer researcher try find people benefit anti-cancer medication people receive amount kind medication . Current study suggest inherit characteristic might explain difference . Height eye color examples characteristic inherited parent . Studies suggest people might also inherit genetic difference body break medication . When person receive anti-cancer medication , break liver small part by-product . To try understand people 's body break anti-cancer medication , researcher study by-product ( call metabolite ) epirubicin blood people take medication part breast cancer treatment .</brief_summary>
	<brief_title>An Investigation Effect Promoter Polymorphism Glucuronosyltransferase 2B7 Patients Breast Cancer Treatment</brief_title>
	<detailed_description>Epirubicin anthracycline widely use breast cancer , stomach esophageal cancer . Despite epirubicin 4'-epi-isomer doxorubicin , epirubicin undergoes substantially different metabolism compare doxorubicin . The majority epirubicin metabolize glucuronides , 78.0 % epirubicin glucuronide 19.3 % epirubicinol glucuronide 0.2 % epirubicin metabolized epirubicinol . Doxorubicin primarily metabolize aglycones doxorubicinol glucuronides . There substantial variability epirubicin metabolism mean clearance 84.6 L/h standard deviation 63.5 . A study Hu et al show epirubicin metabolism correlate response . In study show patient nasopharyngeal cancer treat epirubicin likely relapse rapidly metabolize epirubicin . A study Robert et al raise possibility difference epirubicin metabolism determine genetic difference . They show bimodal distribution ratio epirubicin glucuronides epirubicin . As well study show low glucuronidation likely respond epirubicin patient high ratio epirubicin glucuronides epirubicin . Innocenti et al show epirubicin metabolize glucuronides uridine glucuronosyltransferase 2B7 ( UGT2B7 ) . The study show strong correlation formation morphine-6-glucuronide glucuronidation epirubicin human liver microsome . The researcher recently discover single nucleotide polymorphism enhancer region UGT 2B7 . Patients homozygous polymorphism tend low ratio morphine-6-glucuronide morphine . The researcher suspect T C polymorphism decrease transcription UGT 2B7 basis decrease glucuronidation . Given strong correlation metabolism morphine epirubicin human liver microsomes researcher suspect polymorphism may responsible variability epirubicin metabolism . Previous work document overlap bimodal distribution ratio epirubicin glucuronides examine whether genetic polymorphism responsible . This study examine effect polymorphism metabolism epirubicin . If relationship exist polymorphism epirubicin metabolism may allow accurate dose important chemotherapeutic agent . Objectives : To determine patient receive adjuvant intravenous FEC chemotherapy ( 5-Fluoruracil 500 mg/m2 , epirubicin 100 mg/m2 , Cyclophosphamide 500 mg/m2 ) give every 3 week whether newly discover SNP position -161 T C responsible variability epirubicin metabolism . Participants : Patients receive adjuvant FEC chemotherapy . Patients pre-existing liver disease Gilbert 's syndrome . In patient history liver disease , liver transaminase must less 3 time upper limit normal bilirubin less upper limit normal . Patients must &gt; /= 18 year age . Eligible patient enrol study write informed consent obtain . Baseline characteristic include age , weight , renal function , liver function , concurrent medication ethnic origin obtain medical chart patient . The patient chart review periodically hematological nonhematological toxicity . Outcome data recurrence time recurrence obtain chart . Sample Size : Medical oncologist consider significant difference drug clearance 15 % . Epirubicin 's clearance 84.6 L/h standard deviation 63.5 . The researcher calculate sample size 80 % power detect 15 % difference . Assuming epirubicin 's average clearance comprise three separate group , hypothesis , researcher would need 29 patient genotype show 15 % difference mean clearance different genotype assume coefficient variation 20 % . The known polymorphism amino acid residue 268 allele frequency 50 % . This allele complete linkage disequilibrium new SNP position -160 previous study morphine . Therefore researcher would need approximately 120 patient produce 30 T/T , 60 T/C 30 C/C .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Receiving adjuvant neoadjuvant FEC100 Elevated bilirubin Abnormal liver kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>adjuvant therapy</keyword>
	<keyword>epirubicin</keyword>
	<keyword>uridine glucuronosyl/transferase 2B7</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>